Oritavancin diphosphate
192564-14-0
≥98% by HPLC
1989
(4"R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3"-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-vancomycin, diphosphate,LY 333328,LY-333328
- Data sheet: View or download
- MSDS: View or download
Oritavancin diphosphate is a second-generation, semi-synthetic lipoglycopeptide, that is derived from chloroeremomycin, an analogue of vancomycin. Similar to vancomycin, it contains a core heptapeptide; however, its unique lipophilic side chain provides oritavancin with a prolonged half-life compared to the parent drug. Oritavancin has a multifaceted mechanism of action that displays concentration-dependent effects against gram-positive organisms. Similar to vancomcyin and other glycopeptides, oritavancin inhibits cell wall biosynthesis by binding noncovalently to the D-alanyl-D-alanine terminal ends of the peptidoglycan chain and pentaglycine bridge, thereby inhibiting transglycosylation and transpeptidation.
-20°C